Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

EBP inhibitor DSP-0390

An orally bioavailable inhibitor of emopamil-binding protein (EBP), with potential antineoplastic activity. Upon oral administration, EBP inhibitor DSP-0390 targets, binds to and inhibits the activity of EBP. This inhibits EBP-mediated de novo cholesterol synthesis. As cholesterol is essential for tumor cell proliferation and survival, this inhibits tumor cell proliferation. The inhibition of EBP also results in the accumulation of its substrates zymostenol and zymosterol, and autophagy in tumor cells. EBP, a non-glycosylated type I integral membrane protein of endoplasmic reticulum, plays an important role in cholesterol biosynthesis, autophagy and oligodendrocyte formation, and is overexpressed in certain tumors.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:emopamil-binding protein inhibitor DSP-0390
Code name:DSP 0390
DSP-0390
DSP0390
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search